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Abstract: The aim of this study was to determine the cytotoxic effect of 3-arylidenechromanone (1)
and 3-arylideneflavanone (2) on HL-60 and NALM-6 cell lines (two human leukemia cell lines) and a
WM-115 melanoma cell line. Both compounds exhibited high cytotoxic activity with higher cytotoxicity
exerted by compound 2, for which IC50 values below 10 µM were found for each cell line. For compound
1, the IC50 values were higher than 10 µM for HL-60 and WM-115 cell lines, but IC50 < 10 µM was found
for the NALM-6 cell line. Both compounds, at the concentrations close to IC50 (concentration range:
5–24 µM/L for compound 1 and 6–10 µM/L for compound 2), are not toxic towards red blood cells.
The synthesized compounds were characterized using spectroscopic methods 1H- and 13C-NMR, IR,
MS, elemental analysis, and X-ray diffraction. The lipophilicity of both synthesized compounds was
determined using an RP-TLC method and the logP values found were compared with the theoretical
ones taken from the Molinspiration Cheminformatics (miLogP) software package. The mode of binding
of both compounds to human serum albumin was assessed using molecular docking methods.
Keywords: synthesis; crystal structure; cytotoxic effect; benzoflavanone/chromanone
derivatives; erythrotoxicity
1. Introduction
Flavonoids constitute a large group of natural and synthetic polyphenolic compounds with a wide
range of antioxidant, anti-allergic, anti-inflammatory, anti-microbial, anti-coagulant, anti-cholesterol,
or anti-cancer activities. These properties often depend on unknown structure-related interactions
with nucleic acids and proteins [1,2]. Due to their antioxidant properties, flavonoids interfere with the
initiation, promotion, and progression of cancer. Flavonoids modulate the activities of various enzymes
and receptors involved in several signal transduction pathways, thus affecting cell proliferation,
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apoptosis, as well as the processes of inflammation, angiogenesis, and metastasis [3]. Due to their
multidirectional mechanisms of action, flavonoids are promising candidates for novel anti-cancer
agents and are being extensively investigated for the treatment of neoplastic diseases [3–5]. For instance,
it was found that, in vivo, quercetin exerts a chemo-preventive effect on prostate cancer (reduces
the cell viability) by downregulating the activity of pro-proliferative and anti-apoptotic proteins [6].
Additionally, synthetic derivatives of naturally occurring flavonoids (e.g., derivatives of chroman-4-one
and tiochromane-4-one [7]) are studied for their anti-cancer properties.
3-arylidenechroman-4-ones, a group of naturally occurring homoisoflavones, can be obtained
by the condensation of aryl aldehydes with chroman-4-ones (chromanones). It was first synthesized
by Robinson and co-workers in the early twenties by condensation of chromanon with the
corresponding aryl aldehyde using alcoholic potassium hydroxide as a catalyst [8]. Other catalysts
have also been proposed. In 1979, Levai and Schag synthesized E-3-arylidenechroman-4-ones
using piperidine as a catalyst, while piperidine has also been successfully used as a catalyst for
the synthesis of 3-benzylidenechroman-4-ones and 3-benzylideneflavanones [9,10]. In recent years,
Kupcewicz and co-authors [11], as well as our group [12], have investigated the cytotoxicity of E
and Z isomers of 3-arylideneflavanone derivatives. Those compounds exhibit high cytotoxicity
with IC50 < 10 µM. However, no significant difference in cytotoxicity of E and Z isomers was
observed. In this study the structure of (E)-3-(4-N,N-diethylaminobenzylidene)chroman-4-one (1) and
(E)-3-(4-N,N-diethylaminobenzylidene)-2-phenylchroman-4-one (2) was elucidated using single crystal
X-ray diffraction (XRD), MS, and NMR spectroscopy. Despite being first synthesized in the 1970s [9,10],
compound 1 was presented as an American patent in 2008 [13] and compound 2 was synthesized
in 1993 by Pijewska [14], but their cytotoxic activity has never been studied. The cytotoxicity of
3-arylidenechromanone and flavanone substituted with p-aminodiethyl on C3 atom in benzene ring
has also been investigated. In addition, the lipophilicity (miLogP) of 1 and 2 and their activity against
red blood cells were determined. The mode of binding to human serum albumin (HSA, a protein
important in binding and transport of various drugs [15]) has also been elucidated by molecular
docking methods. Computational docking of ligand binding to target proteins is often performed as
part of Structure-Based Virtual Screening used in drug discovery and this approach enables molecular
interactions with macromolecules to be predicted [16]. We also assess the lipophilicity and their
influence on the various biological properties.
2. Results and Discussion
2.1. Chemistry
The cytotoxic effects of E and Z-isomers of benzylideneflavanone are compared
in a previous paper [11]. The current paper compares the cytotoxicity of chromanone
and flavanone derivatives. (E)-3-(4-N,N-diethylaminobenzylidene)chroman-4-one (1) and
(E)-3-(4-N,N-diethylaminobenzylidene)-2-phenylchroman-4-one (2) synthesized, as described
previously [14] (Scheme 1).
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Scheme 1. Synthesis of compounds 1 and 2 (when R = H or Ph).
Both compounds were fully characterized using IR, 1H-NMR, 13C-NMR, and MS spectroscopy
and elemental analysis.
The ν (C=O) band for compound 1 was observed at 1663 cm−1, and bands typical for aromatic
rings were noted at 1600, 1584, and 1524 cm−1. An IR spectrum of 2 showed a band at 1654 cm−1
and typical bands for the aromatic rings at 1603, 1559, and 1524 cm−1. The 1H-NMR spectrum for
compound 1 revealed the presence of a triplet from -CH3 protons at 1.12 ppm and a quartet around
3.42 ppm corresponding to the CH2 protons (see Figure S1). A singlet for =C-H was observed at δ
5.45 ppm. At δ 6.75 ppm, a doublet for the C2- protons was observed. The characteristic signals δ
7.02–7.85 ppm correspond to the aromatic rotons. The 1H-NMR spectrum for c mpound 2 revealed
the presence of a t iplet from -CH3 protons at 1.12 ppm (s e Figure S2). A quartet c rresponding to
the CH2 protons was observed at δ 3.36 pp . At δ 6.70 ppm a singlet for C2-H protons was noted.
The signals at δ 6.81–7.79 ppm cor espond to the arom tic protons. A singlet for =C-H was observed
at δ 7.94 ppm. In t 13C-NMR spectrum for compound 1, th characteristic CH3 group signal was
found at δ 12.9 ppm, while the -CH2 group was observed at 44.3 ppm (see Figure S1a). The C2-H
carbon signal was observed at δ 78.1 ppm. At δ 181.0 pp , a signal for C=O was observed. In addition
the 13C-NMR spectrum showed the presence of CHarom and Carom signals, which were expected for
the postulated structure of (E)-3-(4-N,N-diethylaminobenzylidene)chroman-4-one. For compound
2, the 13C-NMR spectrum showed the presence of signals located at δ 12.9 ppm, attributed to a CH3
group and at -CH2 group at δ 44.3 ppm (see Figure S2a). In the 13C-NMR spectrum, a -C=O related
resonance was found at δ 181.2 ppm, those for CHarom and Carom were also found. The mass spectrum
revealed a band in 1 at m/z = 308.2, indicating ([M + H]+), and in 2, at m/z = 384, indicating the
presence of an [M + H] ion.
2.2. Molecular Structures
The molecular structure of compound 1 and 2 is presented in (Figure 1). A molecule of
1 consists of two condensed rings (benzene and pyran) with 4-N,N-diethyloaminobenzylidene
substituent in position 3 of the benzopyran ring. It crystalizes in a triclinic system in a P1 space
group with two molecules in the asymmetric unit. The two independent molecules demonstrate
different geometries in the arrangement of the 4-N,N-diethylaminobenzylideno moiety with respect
to the main benzopyran skeleton. In molecule A, it is nearly planar with dihedral angles
C3-C11-C12-C13 −8.32(1) and C3-C11-C12-C17 172.80 (1)◦, while in molecule B, it is rotated by
about 35◦ with the dihedral angles C53-C61-C62-C63 of −35.41(1)◦ and C53-C61-C62-C67 of 148.31
(1). Moreover, the pyran ring slightly v y in con mation. I molecule A, th pyran ing adopts an
envelope conformation with puckering ring parameters [11] Q = 0.300(2)Å, ϕ = 57.0(3), θ = 62.5(2)◦,
and the a ymmetry parameter [12] ∆Cs(C2) = 2.75(1)◦. The corresponding parameters for the pyran
ring in the molecule B are: Q = 0.451(2)Å, ϕ = 44.9(3)◦, θ = 64.6(2)◦, nd the asymmetry parameter
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∆C2(O51-C52) = 14.0(1)◦, which indicates a screw-boat conformation. Valkonen [17] notes that, in the
structure of (E)-3-(4-(dimethylamino)benzylidene)-2,3-dihydro-4H-chromen-4-one, there are also two
independent molecules crystalizing in an asymmetric unit of the Pc group. The benzopyran skeleton
and the 4-dimethylaminobenzylideno moiety are not planar with dihedral angles of 24.96(2)◦ and
49.53(2)◦ for molecules A and B, respectively. For the C6-C10-C2-C12/C9 and C22-C2)-C19-C21/C31,
the corresponding torsion angles of 32.65(2)◦/149.33(2)◦, −29.42(2)◦, and 156.30(2)◦ were reported.
However, the pyran rings adopt a similar conformation: An envelope conformation with the puckering
ring parameters [18] Q = 0.349(2)Å, ϕ = 309.1(2), θ = 58.6(2)◦, the asymmetry parameter [19]
∆Cs(C4) = 7.30(1)◦ for O1/C5/C6/C3/C4/C1 ring, a screw boat conformation with Q = 0.405(2)Å,
ϕ = 143.0(2), θ = 113.5(2)◦, and the asymmetry parameter [20] ∆C2(C24-C29) = 4.91(1)◦ for the
O4/C28/C22/C29/C24/C26 ring
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Figure 1. Molecular structures of 1 and 2, with atom-numbering schemes. The anisotropic displacement
parameters are shown at the 30% probability level. Hydrogen atoms are drawn as spheres of
arbitrary radius.
The crystal packing of 1 is dominated by C-H . . . O and C-H . . . pi interactions (Figure 2).
The molecules A and B are linked by C8-H8 . . . O2 (−1 + x, y, z) and C67-H67 . . . O51 (−1 + x, y, z)
hydrogen bonds, respectively, forming two ribbons, which are further coupled by C56-H56 . . . O2 (x,
1y, z) hydrogen bond that produces a layer. Other C52-H52 . . . O51 (1− x, 1− y, 1− z) interactions are
responsible for creating the 3-D network of hydrogen bonds connecting two layers. In both molecules,
the intramolecular hydrogen bonds C11-H11 . . . O2 and C61-H61 . . . O52 are observed (Table 1).
Table 1. Hydrogen-bonding geometries (in Å, ◦) for structure 1.
D-H H---A D---A D-H---A
C11-H11 . . . O2 0.93 2.35 2.768 (2) 107
C61-H61 . . . O52 0.93 2.45 2.811 (2) 103
C8-H8 . . . O2 i 0.93 2.63 3.198 (2) 120
C67-H67 . . . O51 i 0.93 2.59 3.409 (2) 147
C52-H52A . . . O51 ii 0.97 2.60 3.274 (2) 126
C56-H56 . . . O2 iii 0.93 2.70 3.498 (2) 144
C2-H2B . . . Cg3 iv 0.97 2.87 3.717 (2) 147
C16-H16 . . . Cg7 v 0.93 2.90 3.726 (2) 148
C21-H21C . . . Cg2 iv 0.96 2.95 3.712 (2) 137
C59-H59 . . . Cg7 ii 0.93 2.71 3.545 (2) 150
C69-H69B . . . Cg6 vi 0.96 2.93 3.645 (2) 132
Symmetry codes: (i): −1+x,y,z; (ii): 1 − x, 1 − y, 1 − z, (iii): x, 1+y, z (iv): 1 − x, 1 − y, −z, (v) 1 + x, y, z,
(vi): - x, 1 − y, 1 − z Cg2, Cg3, Cg6, Cg7− centroids of C5/C6/C7/C8/C9/C10, C12/C13/C14/C15/C16/C17,
C55/C56/C57/C58/C59/C60, and C62/C63/C64/C65/C66/C67 rings.
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Figure 2. Chains and layer of (1) supported by C-H . . . O hydrogen bonds (A) that build a 3-D network
of hydrogen bonds (B) and view of equivalent molecules linked by hydrogen bonds (top right).
Compound 2 crystalizes in a monoclin c system in the P21/n space group. The main skeleton of
the molecule consists of fused benzene and pyran ri gs, the latter b ars a phenyl ring at position 2 and
a 4-N,N-diethyloaminobenzylid o substituent a posi ion 3. The C-2 phenyl ring is erpendicular,
while the aminobenzylid ne substituent is nearly co-planar to the pyran ring. T correspo ding
dihedral a gles are: C3-C2-C22-C27 −13.0(2)◦ and C3-C11-C12-C13 19.2(3)◦, while the dihedral angle
betw en the b st plan s of tho e phenyl ring is 83.7(2)◦. In molecule 2, the pyran ring adopts a
dist rted half-boat conform ion with the puckering ring parameters [21] Q = 0.411(2)Å, ϕ = 220.6(3)◦,
θ = 119.2(2)◦, and the asymmetry para er [22] ∆C2(O1-C2) = 7.80(2)◦.
In comparison to previously investigated similar molecules [1 ], the ap ropriate torsion angles
are: −16.4(2)◦ and 32.5(2)◦ ith a dihedral angle observed betwe n the best planes of phenyl rings
52.8(1)◦. The pyran ring also adopts a nearly half boat conformation with puckering parameters [20]
Q = 0.341(2)Å, ϕ = 226.1(3)◦, and θ . ◦
In the crystal packing of 2, hydrogen bonded dimers are observed, and these are stabil zed by
C16-H16 . . . t cti s (1− x, 1− y,−z) (Figure 3). The intramolecular C11-H11 . . . O2 hydrogen
bond is also bserved similar to compound 1. The crystal packing is also enha ced by C-H . . . pi
interactions (Table 2).
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Figure 3. Partial molecular packing of 2 showing hydrogen-bonded dimers generated by C-H . . . O interaction.
Table 2. Hydrogen-bonding geometries (in Å, ◦) for structure 2.
9 D-H H—A D—A D-H—A
C11-H11—O2 0.97 2.39 2.811 (2) 105
C16-H16—O2i 0.93 2.64 3.271 (2) 126
C7-H7 . . . Cg4ii 0.93 2.55 3.475 (2) 172
C14-H14 . . . Cg2iii 0.93 2.84 3.619 (2) 142
Symmetry codes: (i) 1 − x,1 − y, −z; (ii): 1/2 + x, 1/2 − y, −1/2 + z, (iii): −1/2 + x, 1/2 − y, 1/2 + z, Cg2, and Cg4 are
centroids of C5/C6/C7/C8/C9/C10 C22/C23/C24/C25/C26/C27 rings.
2.3. Biol gical Assays
2.3.1. Cytotoxic Activity
The cytotoxicity of the synthesized compounds was evaluated in vitro by the MTT assay using
three human cancer cell lines HL-60, NALM-6, and WM-115. The results, expressed as inhibitory
concentration (IC50), are shown in Table 3. Compound 2 exhibited high cytotoxic ctivity with
IC50 = 6.45 ± 0.69 µM, which is nine times lower than for 3-benzylideneflavanone nd 154 times
lower than for 4-chromano e, the r ference compounds us in the WM-115 cell line. For the
other cell lines, IC50 values were also satisfactory. In the NALM-6 cell culture, c mpound 1
showed an IC50 value almost 78 times lower than for 4-chromanone and more than three-fold lower
than for 3-benzylideneflavanone. Perjesi and coworkers [23] also reported cytotoxicity of a series
of 3-b nzylid ne-4-chromanones towards several cell lines. The auth rs found that most of the
compou ds inhibit d the growth of 50% of HL-60 cells at the concentrations between 3–28 µM with
3-(3-bromobenzylide e)-2,3-dihydro-1-benzopyran-4-one as the most active. In the current study we
reveal that both synt sized compounds (1 and 2) exhibit good a ti-proliferativ properties at low
micro olar range which make them promising candidates for further in vitro and in vivo studies.
Table 3. The cytotoxic activity of (E)-3-(4-N,N-diethylaminobenzylidene)chroman-4-one (1) and
(E)-3-(4-N,N-diethylamino)benzylidene)-2-phenylchroman-4-one (2) against cancer HL-60, NALM-6,
and WM-115. The results are presented as IC50 values in µM range.
Com ounds
IC50 (µM)
HL-60 NALM-6 WM-115
1 11.76 ± 1.97 8.69 ± 0.40 18.09 ± 3.14
2 8.36 ± 0.63 9.08 ± 0.30 6.45 ± 0.69
4-chromanone 676.7 32.6 673.7 ± 22.5 >1000
3-benzylideneflavanone [11] 3 .3 3.0 29.5 ± 4.7 59.4 ± 0.9
Molecules 2018, 23, 3172 7 of 16
2.3.2. Rbcs Lysis Assay
In studies on the integrity of the erythrocyte membrane, statistically significant results in
comparison with saline control were obtained for compound 2 at the highest concentrations tested
(9 and 10 µmol/L) (Figure 4), which implies that compounds at these concentrations contributed to
red blood cell breakdown. However, the values of hemolysis did not exceed 10%, which is considered
to be a clinically important threshold of cytotoxicity [24].
In contrast, compound 1 did not lead to any significant increase in the hemolysis rate, therefore,
it might be concluded that both examined compounds do not show adverse effects on the integrity of
the red blood cells (RBCs) membrane over the entire concentration range.
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2.3.3. RBCs Morphology
When a drug molecule is administered intravenously a series of interactions with blood cells
might be initiated. The effects of 1 and 2 on the morphology of erythrocytes were visualized by
microscope studies (Figure 5).
Both tested compounds 1 and 2, contributed to the formation of echinocytes. Echinocytes accounted
for the major part of erythrocytes when 24 µmol/L compound 1 was applied. As presented in
Figure 5, compound 2 led to the formation of echinocytes over the entire concentration range, however,
the percentage of this erythrocyte form differed according to the concentration of 2. The transformation
of biconcave erythrocytes to echinocytes occurs naturally in blood vessels, and could be also seen in
control samples. It has been proved that echinocytosis is a reversible transformation caused by various
chemical and physical factors including increased ion strength, alkaline pH, and decreased in adenosine
triphosphate (ATP) level [25].
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2.4. o p tatio al t dies
e r s circ late i l , t e i teract it i l ical acr lec les s c as las a
r tei s; t ese al i s c stit te t e aj rit a are i rta t i t e ar ac i etics f
e ici es. r derivatives 1 and 2, tenfold blind experiments of docking to HSA were performed
to establish locations of their bi ding sites and the strength of the hypothetical interactions.
The c mpounds were found to bind t rough hydrophobic interactions, 1 in four different places
(near the cleft site, at the IB and FA1 sites, above the IIA—drug site and some additional aty ical place)
with average ∆G◦ −7.5 kcal/mol, whereas 2, only in the IB FA1 site with average ∆G◦ −9.5 kcal/mol
(Figure 6A,B). This single binding most likely resulted from the presence of an additional phenyl
ring at the C2 position. The pi . . . pi stacking was an important interaction between phenyl rings
of the docked compounds and th aromatic side chains of tyrosine d phenylalanine. In the IB
FA1 site, the ar matic rings of Tyr138 and 4-di th loaminobenzylidene substituent were parallel
and were only slightly offset from each other with a distance between 4.4 and 4.5 Å. The phe yl
ring in position 2 was locat d between the phenyl rings of Tyr138 and Phe125. The pyran ring was
located between the phe yl ring of Phe125 nd the aliphatic chain of Lys137 (Figure 6C,D). In c ntrast,
comp und 1 was located in the IB FA1 site inversely and showed less potent hydrophobic interactions.
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The rings of the 4-N,N-diethyloaminobenzylidene substituent and Tyr138 were arranged in a parallel
orientation, but were much more offset. The pyran ring was perpendicular to the phenyl ring of
Tyr140 with a distance greater than 5 Å. His247 and Tyr30 were isolated with the distance greater than
20 Å. For compound 1, mainly hydrophobic interactions with the aliphatic amino acid residues were
observed in the other binding sites, and in the case of the cleft site, an oblique interaction between the
pyran ring with the Tyr452 phenyl ring could be possible within a distance of 3.6 Å. In one atypical
place, a similar interaction with the imidazole ring of His146 could take place within a distance of
3.3 Å. No specific hydrogen bonds were detected for either compounds.
To predict other properties of compounds 1 and 2, the Molinspiration web tool was used and
the drug descriptors were counted. For the Molinspiration GPCR ligand, Ion channel modulator,
Kinase inhibitor, Nuclear receptor ligand, enzyme inhibitor and protease inhibitor bioactivity the
scores were < zero or near zero, indicating that the compounds were not typical inhibitors or agonists
of the listed types of proteins. Ligand efficiencies (LE) for derivatives calculated from computationally
estimated ∆G◦ and known number of heavy atoms, theoretical logP and logP/LE (LELP), divided by
the predicted number of binding sites were different for two compounds, but were still within the
range of drug-likeliness (Table 4).
The experimental lipophilicity of the synthesized compounds was determined using RP-TLC: logP
values 3.43 was obtained for compound 1 and 5.69 for compound 2. Theoretical values of lipophilicity
were calculated using Molinspiration Cheminformatics (miLogP):milogP 4.47 was obtained for
1 and 6.05 for 2, i.e., similar to those obtained experimentally. Greater values of experimental
and theoretical lipophilicity were noted for 2 because of the presence of the phenyl ring in the
C2 position. Thus, molecular docking and Molinspiration predictions suggest that 1 and 2 have greater
hydrophobicity than 1, but also indicate potential specificity influence of an additional phenyl ring.
Table 4. Molinspiration bioactivity score and drug likeliness. H.A., the number of heavy atoms, n,
number of binding sites, and LE, Ligand Efficiency (−∆G◦/H.A.), LELP (logP/LE).
Compound Bioactivity Score H.A. n ∆G
◦ Bind
(kcal/mol)
LogP
(exp) miLogP LE LELP
1
GPCR ligand −0.15
Ion channel modulator −0.30
Kinase inhibitor −0.30
Nuclear receptor ligand −0.04
Protease inhibitor −0.38
Enzyme inhibitor −0.11
23 4 −7.5 3.43 4.47 0.33 13.55
2
GPCR ligand −0.04
Ion channel modulator −0.32
Kinase inhibitor −0.26
Nuclear receptor ligand 0.03
Protease inhibitor −0.31
Enzyme inhibitor −0.08
29 1 −9.1 5.69 6.05 0.31 19.52
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Figure 6. Tenfold blind docking of derivative 1 and 2 to HSA. Ribbon-stick models present the docking
of derivatives (sticks) I-A, C and II-B, D to 1E7I human albumin structure (ribbon) with binding affinity
energy (∆G◦) −7.5 ± 0.2 and −9.1 ± 0.1 (kcal/mol ± SD), respectively. C, D are the zoom of IB
FA1 binding site area, distances marked by yellow dashe lines.
3. aterials and ethods
The second co pound 2 as synthesized according to Pije ska [14]. Co pounds 1 and 2 ere
purified by crystallization fro ethanol. ll solvents ( ethanol, ethanol, and toluene) used in this
ork ere purchased from Sigma-Aldrich (St. Louis, MO, USA) and POCH (Gliwice, Poland) chemical
companies and were used without further purification.
elting points were determined on a Büchi Melting Point B-540 apparatus in the capillary
mode and they were uncorrected. The infrared transmission spectra of the crystalline products ere
recorded using a Nexus Thermo Nicolet FT-IR spectrophotometer (Wien, Austria; Faculty of Chemistry,
University of Lodz). The MS-ESI were measured on Varian 500, MS LC Ion Trap mass spectro eter
(Santa Clara, CA, United States; Faculty of Chemistry, University of Lodz). Elemental analyses were
performed in the Faculty of Chemistry (University of Lodz) using a Vario Micro Cube (Langenselbold,
Germany) by Elemental analyzer. 1H- and 13C-NMR spectra were recorded on a Bruker Avance III
600 MHz (Karlsruhe, Germany). Both samples were dissolved in DMSO deuterated. Chemical shifts
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are given in ppm, coupling constants in Hz. Computational studies were used to predict the properties
and future use of potential drugs. Molinspiration Cheminformatics (http://www.molinspiration.com/
products.html) was used for the calculation of important molecular properties, molecular processing,
bioactivity, and the high-quality depiction of new molecules. Molecular docking of the compounds to
the HSA crystal structure 1E7I [21] was performed in AutodockVina 1.1.2 (http://vina.scripps.edu) [22],
as previously described [12].
Lipophilicity was determined using an RP-TLC method with small amounts of organic solvents.
Assessment of erythrotoxicity of compounds 1 and 2 was made in Laboratory of Bioanalysis in
the Department of Pharmaceutical Chemistry, Drug Analysis, and Radiopharmacy in the Medical
University of Lodz. The erythrocyte morphology was evaluated using a phase-contrast microscope
Opta-Tech (Warsaw, Poland) using the OptaView 7 programme. Biological material (blood) for research
came from the Regional Blood Donation Center in Lodz.
3.1. Synthesis of (E)-3-(4-N,N-diethylaminobenzylidene)chroman-4-one (1)
A mechanically stirred mixture of 10 mmol of chroman-4-one, 10 mmol
4-N,N-diethylaminobenzaldehyde and five drops of piperidine was heated at 140 ◦C in an oil
bath for 4 h. After cooling the reaction mixture was left for 24 h at room temperature. Next, methanol
was added and the resulting was filtered and crystallized from methanol. Compound 1 was thus
obtained as a light orange powder.
Yield: 33.5%. M.p. 124.9–125.4 ◦C. MS (ESI+): m/z 308. C20H21NO2 [M + H]+. IR (KBr) ν (cm−1):
3037 (C-Haromat), 2968, 2923, 2895, 2870 (C-Haliph), 1663 (C=O), 1600, 1584, 1524 (C=C), 1154 (C-O-C).
1H-NMR (600 MHz, DMSO-d6) δ (ppm): 1.12 (3H, t, JH-H—6 Hz, CH3), 3.42 (2H, q, JH-H—6 Hz,
CH2), 5.45 (1H, s, CH), 6.75 (2H, d, JH-H—6 Hz, C2-H), 7.02 (1H, d, JH-H—12 Hz, C4-Harom), 7.09 (1H,
t, JH-H—6 Hz, C6-Harom), 7.32 (1H, d, JH-H—6 Hz, C8-Harom), 7.54 (1H, t, JH-H—6 Hz, C7-Harom),
7.84 (1H, d, JH-H—6 Hz, C6′-Harom), 7.85 (1H, d, JH-H—6 Hz, C5′-Harom). 13C-NMR (600 MHz,
DMSO-d6) δ (ppm): 12.9 (CH2CH3), 44.3 (CH2CH3), 68.4 (C-2), 111.6, 118.1, 120.8, 122.2, 122.4, 125.2
(CHarom, =CH), 135.9, 133.7, 137.9, 149.2, 160.7 (Carom), and 181.0 (C=O). Anal. Calc. for C20H21NO2
(M = 307.386 g/mol) % C:78.14; and % H: 6.89. Found % C: 78.16; and % H: 7.06.
3.2. Synthesis of (E)-3-(4-N,N-diethylaminobenzylidene)-2-phenylchroman-4-one (2)
The compound 2 was synthesized according to Pijewska in 1993 [14]. A racemic mixture
was obtained.
Yield: 34%. M.p. 170–171 ◦C (MeOH). MS (ESI+): m/z 384. C26H25NO2 [M + H]+. IR (KBr)
ν (cm−1): 3056 (C-Haromat), 2965, 2920, 2895, 2863 (C-Haliph), 1654 (C=O), 1603, 1559, 1524 (C=C),
1150 (C-O-C). 1H-NMR (600 MHz, DMSO-d6) δ (ppm): 1.12 (3H, t, JH-H—6 Hz, CH3), 3.36 (2H, q,
JH-H—6 Hz, CH2), 6.70 (1H, s, C2-H), 6.81–7.79 (13H, m, C-Harom), 7.94 (1H, s, =CH). 13C-NMR
(600 MHz, DMSO-d6) δ (ppm): 12.9 (CH2CH3), 44.3 (CH2CH3), 78.1 (C2-H), 119.0, 120.2, 125.9, 127.2,
127.9, 129.1, 129.3, 136.2, 138.6, 140.3 (CHarom, =CH), 122.3, 122.7, 122.7, 133.7, 149.6, 158.5 (Carom), 181.2
(C=O). Anal. Calc. for C26H25NO2 (M = 389.529 g/mol) % C: 81.43; % H: 6.57; % N: 3.65. Found % C:
81.57; % H: 6.78; and % N: 3.58.
3.3. Determination of Lipophilicity of Flavone Derivatives Using RP-TLC Method
The RP-TLC experiments were performed on TLC plates (5 × 10 cm) RP-18 F254S (Merck,
Darmstadt, Germany). The synthesized compounds were dissolved in N,N-dimethylformamide
DMF (2 mg/mL). High purity DMF 99.8% was obtained from Chempur (Piekary Slaskie, Poland).
The solutions of each compound in DMF were spotted on plates. The spots were observed under
UV light at λ = 254 nm. DMF-water solvent system was used as mobile phase. The composition
of the solvent system changed from 50%:50% to 95%:5%. All experiments were performed at room
temperature. The LogP parameter was calculated using the equation from the calibration curve.
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3.4. X-ray Diffraction Experiment
The X-ray single crystal diffraction experiments for 1 and 2 were performed using an Agilent
SuperNova diffractometer equipped with an Atlas detector at T = 100(2)K with monochromatic MoKα
radiation (λ = 0.71073 Å). Multi-scan absorption correction was applied to all data [26]. All structures
were solved by direct methods using SHELX and further refined on F2 using SHELX-2014/7 [27].
The position of the hydrogen atoms were calculated from the known geometry (C-H bond lengths
at 0.93, 0.96, and 0.97 Å for aromatic CH, methylene CH2, and CH3 methyl atoms, respectively)
and treated as riding, where isotropic thermal parameters of these hydrogen atoms were fixed as
Uiso(H) = 1.2 Ueq(C) (for aromatic and methylene H atoms) or Uiso(H) = 1.5 Ueq(C) for (methyl
H-atoms). Key experimental crystallographic data and refinement details of the studied compounds
1 and 2 are summarized in Table 5. To identify molecular geometries and hydrogen-bond patterns,
PLATON and Mercury [28] were utilized. CCDC 1877734 (compound 2) and 1877735 (compound 1)
contains the supplementary crystallographic data for this paper. These data can be obtained free of
charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by
contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK;
fax: +44-1223-336-033.
Table 5. Crystal data, data collection, and refinement parameters of 1 and 2.
1 2
Crystal data
Chemical formula C20H21NO2 C26H25NO2
Mr 307.38 383.47
Cell setting, space group Triclinic, P-1 Monoclinic, P21/n
a, b, c (Å) 7.732(2),13.998(2), 16.312(2) 11.764(2), 13.455(2), 12.832(2)
α, β, γ (◦) 64.74(2), 87.07(2), 87.58(2) 90.0, 93.75(2), 90.0
V (Å3) 1594.1(2) 2026.8(2)
Z 4 4
Dx (Mg m−3) 1.376 1.257
Temperature (K) 100 100
Radiation type (Å) 0.71073 0.71073
µ (mm−1) 0.082 0.079
Crystal form, colour prism, colourless block, orange
Crystal size (mm) 0.3 × 0.2 × 0.18 0.3 × 0.2 × 0.18
Data collection
Diffractometer SuperNova, Atlas detector SuperNova, Atlas detector
No. of measured and unique reflections 13098, 6603 25887, 4193
Observed data with F2 4σ(F2) 5664 3316
Rint 0.0265 0.0305
θmax (◦) 26.49 26.49
Overall completeness to θmax [%] 99.8 99.8
Refinement (SHELX)
Refinement on F2 F2
All data 6603 4193
R, wR [I 2 (I)] 0.0362, 0.0941 0.0513, 0.1347
R, wR (all data) 0.0434, 0.0989 0.0686, 0.1453
Goodness of fit 1.067 1.066
No. of parameters 419 268
ρmax, ρmin (eÅ−3) 0.249, −0.212 0.241, −0.265
3.5. Cells Cultures and Cytotoxicity Assay by MTT
Cytotoxicity was tested against human skin melanoma cells (WM-115 ECACC, Salisbury, UK),
and two human leukemia cell lines—promyelocytic leukemia (HL-60) and lymphoblastic leukemia
(NALM-6). The leukemia cells were cultured in RPMI 1640 medium (Invitrogen, Grand Island, NY,
USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Grand Island, NY, USA) and
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gentamicin (25 µg/mL; KRKA, Slovenia). For melanoma WM-115 cells, Dulbecco‘s minimal essential
medium (DMEM; Invitrogen, Grand Island, NY, USA) 1640 was used. Cells were grown at 37 ◦C in a
humidified atmosphere of 5% CO2 in air.
For all experiments, the studied compounds were dissolved in DMSO (Sigma-Aldrich, St. Louis,
MO, USA) and were further diluted in a culture medium to obtain <0.1 % DMSO concentration. In each
experiment control without and with 0.1% DMSO was performed.
The cytotoxicity of both compounds, and the reference compounds (4-chromanone and
3-benzylidene-flavanone) was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT; Sigma, St. Louis, MO, USA) assay, which measures the activity of cellular
dehydrogenases [29]. Exponentially growing cells were seeded on 96-well plates (Nunc, Roskilde,
Denmark). Subsequently, various concentrations of the studied compounds (freshly prepared in
DMSO and diluted with complete culture medium) were added. All compounds were tested for
their cytotoxicity at a final concentration of 10−7–10−3 M. After 46 h of incubation with the studied
compounds, the cells were treated with the MTT reagent and incubation was continued for another
two hours. The MTT formazan crystals were dissolved in 20% SDS (Sodium dodecyl sulphate,
Sigma-Aldrich, St. Louis, USA) and 50% DMF (Sigma-Aldrich, St. Louis, MO, USA) at pH 4.7, and the
absorbance was read at 570 nm on a multifunctional Victor ELISA-plate reader (Perkin Elmer, Turku,
Finland). The IC50 values, the concentration of the test compound, was required to reduce the cell
survival fraction to 50% of the controls, and were calculated from concentration response curves and
was used as a measure of the sensitivity of the cells to a given treatment. As a control, cultured cells
were grown in the absence of drugs. The data points represent the means of at least five to ten repeats
± S.D (standard deviation).
3.6. Red Blood Cells Lysis Assay
The studies on biological material were approved by the Bioethics Committee of the Medical
University of Lodz, Poland (RNN/27/18/KE). The blood from healthy donors (Blood Donation Centre
in Lodz) was collected in tubes containing a solution of potassium EDTA. RBCs were isolated by
centrifugation (3000× g, 10 min) at 20 ◦C and washed three times with 0.9% saline. The studies were
performed on four biological samples obtained from different blood donors.
The effects of (E)-3-(4-N,N-diethylaminobenzylidene)-2-phenylchroman-4-one 1 and
(E)-3-(4-N,N-diethylaminobenzylidene)-2-phenylchroman-4-one 2 on RBCs was performed using
the method described earlier [30,31]. Briefly, 2% RBCs suspension prepared in 0.9% saline was incubated at
37 ◦C with tested compounds added in a 10 µL volume for one hour. The percentage of solvent (methanol)
did not exceed 1% of the final sample volume (1 mL). Afterwards, the samples were centrifuged at
1000× g for 10 min (20 ◦C), and the absorbance of the supernatant was measured at 550 nm wavelength
(spectrophotometer (Cecil CE2021, London, England)). Samples containing saline solution were used to
measure spontaneous hemolysis of RBCs, while samples with Triton X-100 ((2.0% v/v); Polish Chemical
Reagents) constituted 100% of hemoglobin release. The results are presented as a percentage of released
hemoglobin. The examined concentrations of tested compounds were chosen on the basis of obtained IC50
values determined for three human cancer cell lines: HL-60, NALM-6, and WM-115.
3.7. RBCs Morphology
A 2% erythrocyte suspension was incubated at 37 ◦C for 1 h with various concentrations of tested
compounds. The morphology of the RBCs was evaluated using a phase contrast Opta-Tech inverted
microscope, at 400 times magnification, equipped with image analysis software (OptaView 7).
3.8. Statistical Analysis
Statistical analysis was conducted with a commercially available package (Statistica 12.0, StatSoft).
All results are presented as mean ± SD. The normality of the distribution of continuous variables was
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confirmed with the Shapiro-Wilk test. Paired t-tests were used for intergroup comparisons of normally
distributed variables. The results were considered significant at p-values lower than 0.05.
4. Conclusions
This study presents the synthesis, chemical characterization, and biological activity of
3-benzylidenederivatives of chromanone and flavanone. The structure of synthesized compounds
was confirmed using NMR, MS, IR, and single crystal X-ray diffraction (XRD) techniques.
The anti-cancer properties of synthesized compounds 1 and 2 were evaluated using HL-60, NALM-6,
and WM-115 cancer cell lines. Both compounds exerted a greater cytotoxic effect towards all cell
lines than the reference 4-chromanone and 3-benzylideneflavanone. Compound 2 exerted the most
profound cytotoxic effect towards WM-115 cell line with IC50 = 6.45 ± 0.69 µmol/L. Lipophilicity of
both compounds was determined using an RP-TLC method. Due to the presence of a phenyl
substituent in the C2 position of chromanone, the value of logP for compound 2 was higher than
that for 1. Both compounds did not affect the integrity of erythrocyte membrane over the examined
concentration range and did not contribute to hemolysis. In addition, tested compounds did not
induce the pathological changes in the morphology of erythrocytes since only dyscocytes and
echinocytes were recognized. Thus, both compounds at the concentrations close to the determined
IC50 values might be regarded as biocompatible towards red blood cells. Computational studies
suggest remarkably different ability of the synthetized compounds to bind with HSA, and different
specificity as far as the future use as drugs is considered. Taking into consideration the promising
cytotoxicity properties, i.e., IC50 values in a few micromolar range and being harmless to the red
blood cells, the arylidenechromanone/flavanone derivatives can be further evaluated as promising
anticancer compounds.
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